

# Risankizumab

## Adjudication Guideline

**Rule Category:**  
Pharmaceutical

**Ref: No:**  
2023-PH-21

**Version Control:**  
Version No. V1.0

**Effective Date:**  
01<sup>st</sup> April 2023

**Last Update:**  
05/06/23

**Approved by:**  
Daman

**Responsible:**  
Medical Standards  
& Research

**Related Adjudication  
Guidelines:** NA

## Table of Contents

1.	Abstract .....	3
1.1	For Members.....	3
1.2	For Medical Professionals.....	3
2.	Scope .....	3
3.	Adjudication Policy.....	3
3.1	Eligibility / Coverage Criteria.....	3
3.2	Requirements for Coverage .....	4
3.3	Non-Coverage.....	4
3.4	Payment and Coding Rules .....	4
4.	Denial codes .....	5
5.	Appendices .....	5
5.1	References .....	5
5.2	Revision History .....	5

## 1. Abstract

### 1.1 For Members

Risankizumab can only be obtained with a prescription and should be used under the supervision of a doctor experienced in diagnosing and treating plaque psoriasis, psoriatic arthritis or Crohn's disease.

### 1.2 For Medical Professionals

Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody selective to the interleukin (IL)-23 protein produced in Chinese Hamster Ovary cells using recombinant DNA technology.

## 2. Scope

The scope of this adjudication rule is to highlight the medical indications, and coverage details for Risankizumab as per the policy terms and conditions of each health insurance plan administered by Daman.

## 3. Adjudication Policy

### 3.1 Eligibility / Coverage Criteria

Ustekinumab is an interleukin-23 antagonist indicated for the treatment of:

1. **Plaque psoriasis** <sup>1,2</sup>: is indicated to treat adults with moderate to severe plaque psoriasis. It reduces inflammation and can therefore help reduce symptoms of plaque psoriasis such as burning, itching, pain, redness, and scaling.
2. **Psoriatic arthritis (PsA)** <sup>1,2</sup>: is indicated to treat adults with psoriatic arthritis.
3. **Moderate-to-severe Crohn's disease** <sup>3</sup>: IS indicated in adults when conventional or biological treatments do not work well enough or cause unacceptable side effects.

#### **Pre-treatment Evaluation** <sup>1</sup>:

- Evaluate patients for tuberculosis (TB) infection prior to initiating treatment.
- Complete all age-appropriate vaccinations as recommended by current immunization guidelines.

#### **Dosage and Administration** <sup>1,2</sup>:

The recommended dosage is 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter, (either as two 75 mg pre-filled syringe injections or one 150 mg pre-filled pen or pre-filled syringe injection).

Two formulations are used for Crohn's disease. The first, a concentrate, is used to make a solution which is given at the start of treatment as an infusion (drip into a vein) three times over eight weeks. The second formulation, a solution for injection in a cartridge, is for long-term maintenance treatment and is given as an injection under the skin 4 weeks after the last infusion and then every 8 weeks thereafter <sup>3</sup>.

#### **Missed dose** <sup>2</sup>:

If a dose is missed, the dose should be administered as soon as possible. Thereafter, dosing should be resumed at the regular scheduled time

**Dosage forms and strengths available <sup>1</sup>:**

1. **Risankizumab Pen Injection:** 150 mg/mL as a colourless to yellow and clear to slightly opalescent solution in each single-dose prefilled pen.
2. **Risankizumab Prefilled Syringe Injection:** 150 mg/mL as a colourless to yellow and clear to slightly opalescent solution in each single-dose prefilled syringe.
3. **Risankizumab Injection:** 75 mg/0.83 mL as a colourless to slightly yellow and clear to slightly opalescent solution in each single-dose prefilled syringe.

**WARNINGS AND PRECAUTIONS <sup>1</sup>:**

- Avoid use of live vaccines in patients treated with Risankizumab
- In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, Risankizumab should be used with caution. Treatment with Risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

**Pediatric Use <sup>1</sup>:**

The safety and efficacy of RISANKIZUMAB in pediatric patients younger than 18 years of age have not yet been established.

**Discontinuing treatment <sup>2</sup>:**

Consideration should be given to discontinuing treatment in patients who have shown no response after 16 weeks of treatment. Some plaque psoriasis patients with initial partial response may subsequently improve with continued treatment beyond 16 weeks.

### 3.2 Requirements for Coverage

- Failure to submit, upon request or when requesting a clinical history, indication the need for testing will result in rejection of claim.
- Kindly code the ICD-10 and the CPT codes to the highest level of specificity
- Eligible clinician specialities

Eligible clinician speciality
Dermatologist
Rheumatologist
Gastroenterologist

### 3.3 Non-Coverage

- Not covered for visitor plan
- Age less than 6 years

### 3.4 Payment and Coding Rules

Kindly apply DOH payment rules and regulations and relevant coding manuals for ICD, Drugs.

## 4. Denial Codes

Regulator denial codes with description are elaborated for reference. These are specialized codes directed by regulator, that explains the reason of rejection of the service by DAMAN to the providers.

Code	Code Description
CODE-010	Activity/diagnosis inconsistent with clinician specialty
MNEC 004	Service is not clinically indicated based on good clinical practice
MNEC 003	Diagnoses are not covered
AUTH-001	Prior approval is required and was not obtained

## 5. Appendices

### 5.1 References

- [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/761105s014lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761105s014lbl.pdf)
- <https://www.medicines.org.uk/emc/product/12625/pil#gref>
- [https://www.ema.europa.eu/en/documents/overview/risankizumab-epar-medicine-overview\\_en.pdf](https://www.ema.europa.eu/en/documents/overview/risankizumab-epar-medicine-overview_en.pdf)

### 5.2 Revision History

Date	Change(s)
31/03/2023	Release of V1.0
05/06/2023	Updated: added Gastroenterologist

#### Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.

